FAQs about fenebrutinib in MS

Fenebrutinib is an experimental medicine that has not been approved for any indication, and that is still in clinical trials for multiple sclerosis. The therapy is believed to help reduce the inflammation that causes neurological damage in MS by blocking the activity of the Bruton tyrosine kinase protein, which is integral to the inflammatory activity of B-cells and microglial cells.

Fenebrutinib is currently being tested in multiple sclerosis patients in three Phase 3 clinical trials, all of which are expected to conclude in 2025. If the results of these studies are positive, it is possible that they could support regulatory applications seeking the therapy’s approval by the U.S. Food and Drug Administration. But it is too early to know if or when fenebrutinib could be approved to treat MS.

Current clinical trials in multiple sclerosis are not enrolling participants who are pregnant, and those with the ability to conceive are required to take measures to prevent conception while in the study. As such, it is currently unknown whether fenebrutinib can be safely taken during pregnancy.

There are not yet any data available on the potential efficacy of fenebrutinib in people with multiple sclerosis.

Neither hair loss nor weight gain was reported as side effects associated with fenebrutinib in clinical trials that enrolled participants with other inflammatory conditions. It remains unknown if these effects are experienced by people with multiple sclerosis.

Related Articles